Paris diagnostics developer buys stake in Corgenix

Justine Varieur Cadet | | Health Imaging | Enterprise Imaging
Corgenix Medical, a developer and marketer of diagnostic test kits, and the ELITech Group, a Paris-based group of companies and a distributor of in-vitro diagnostic equipment and reagents, have signed an alliance that includes investment, distribution and product development.

Terms of the agreement include:
  • Investment: ELITech will initially purchase 8.33 million shares of Corgenix common shares at $0.15 per share. ELITech is also committing to invest another $750,000 in Corgenix common stock at the same price over the subsequent 12 months upon the successful completion by Corgenix of the two events specified below; warrants also issued at $0.15 could potentially result in an additional $1 million investment.
  • International Distribution: ELITech will become the master distributor for Corgenix outside of North America.
  • Product Development: Corgenix and ELITech will co-develop new tests by combining Corgenix products and technologies with several of the ELITech proprietary instrument systems.

Justine Varieur Cadet

Related Content

Less than half of incidental interstitial lung abnormalities on CT exams are reported
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Rads are more accurate when they have access to patients' self-reported symptoms
AI-based software improves follow-up imaging adherence by 74%

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.